Digital Look

Welcome to Digital Look++,
you are not logged in

Avacta Group (AVCT)

Pharma and Biotech

67.50p

Trade now with Barclays Stockbrokers

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Jun-26	Interim	0.06	(18.85)	(4.23)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	2.94	(29.19)	(10.57)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	9.65	(41.64)	(14.48)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	2.85	(31.12)	(10.69)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	0.11	(28.98)	(8.54)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	0.11	(36.84)	(9.27)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-26	1.87	(26.38)	(6.14)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	8.10	(30.75)	(5.39)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.